Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ferrandina

Showing results (61-70 of 176) with videos related to

Pageof 18
Sort By:
Cancer Letters|September 4, 1995
Interaction of tamoxifen with cytosolic and nuclear type II estrogen binding sites (type II EBS)G Ferrandina, F O Ranelletti, G Scambia, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|October 2, 2004
Sonographic features of decidualized ovarian endometriosis suspicious for malignancyE Fruscella, A C Testa, G Ferrandina, et al.
Oncology|November 5, 1999
IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levelsE Foti, G Ferrandina, R Martucci, et al.
Minerva Ginecologica|May 6, 2009
Advances in surgical management of cervical cancerA Ercoli, V Iannone, F Legge, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 6, 2013
Pre-hysterectomy cone biopsy is able to predict response in locally advanced cervical cancer patients submitted to neo-adjuvant chemoradiationF Fanfani, A Fagotti, M L Gagliardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissuesM Marone, G Scambia, S Mozzetti, et al.
British Journal of Cancer|October 2, 2003
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancerG D'Agostino, G Ferrandina, M Ludovisi, et al.
Cancer|September 26, 2001
GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapyG Cantuaria, A Fagotti, G Ferrandina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Significance of epidermal growth factor receptor in advanced ovarian cancerG Scambia, P Benedetti Panici, F Battaglia, et al.
Oncology|January 1, 1991
Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancerM Castelli, F Battaglia, G Scambia, et al.
Pageof 18

Showing results (61-70 of 176) with videos related to

Sort By:
Pageof 18
Cancer Letters|September 4, 1995
Interaction of tamoxifen with cytosolic and nuclear type II estrogen binding sites (type II EBS)G Ferrandina, F O Ranelletti, G Scambia, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology|October 2, 2004
Sonographic features of decidualized ovarian endometriosis suspicious for malignancyE Fruscella, A C Testa, G Ferrandina, et al.
Oncology|November 5, 1999
IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levelsE Foti, G Ferrandina, R Martucci, et al.
Minerva Ginecologica|May 6, 2009
Advances in surgical management of cervical cancerA Ercoli, V Iannone, F Legge, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 6, 2013
Pre-hysterectomy cone biopsy is able to predict response in locally advanced cervical cancer patients submitted to neo-adjuvant chemoradiationF Fanfani, A Fagotti, M L Gagliardi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissuesM Marone, G Scambia, S Mozzetti, et al.
British Journal of Cancer|October 2, 2003
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancerG D'Agostino, G Ferrandina, M Ludovisi, et al.
Cancer|September 26, 2001
GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapyG Cantuaria, A Fagotti, G Ferrandina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
Significance of epidermal growth factor receptor in advanced ovarian cancerG Scambia, P Benedetti Panici, F Battaglia, et al.
Oncology|January 1, 1991
Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancerM Castelli, F Battaglia, G Scambia, et al.
Pageof 18